Forecast of the application structure, market size and competition pattern of the peptide drug industry (with report catalogue)
Structural analysis of peptide drug applications
The quality control level of peptide drugs is close to small molecule chemical drugs, and the activity is close to protein drugs. Combining the advantages of the two, it shows its own superiority in clinical application and production and preparation, with high activity, low dose, and low dose. The advantages of toxicity, etc., are suitable for solving complex diseases that are difficult to solve by small molecule chemical drugs.
However, polypeptide drugs also have the disadvantages of high production cost and inconvenient administration. The large-scale production of peptide drugs is difficult. At present, chemical synthesis is the main way for the large-scale production of peptide drugs.
Based on the above characteristics of peptide drugs, the current main application areas include acute and chronic diseases. Polypeptide drugs were first popularized in the field of emergency and rescue, because the drugs in this field are generally surgical treatment, which is injected intravenously by doctors and nurses, and is a one-time treatment.
There is no problem of inconvenience in administration, and long-term administration is not required. Patients have a high degree of acceptance of drug prices. At present, octreotide acetate, somatostatin, and terlipressin acetate are used for emergency hemostasis, and bivarudine, eptifibatide, and nesiritide are used for cardiac first aid.
Carbetocin and other drugs that prevent postpartum hemorrhage are all such drugs. In the field of chronic diseases, polypeptide drugs have a greater competitive advantage in the case of poor treatment effects of certain traditional drugs, such as immune regulation, cardiovascular system diseases, diabetes, osteoporosis, tumors, rare diseases lacking treatment methods, etc. It has been widely used.
Related report: Beijing Puhua Youce Information Consulting Co., Ltd., “2021-2027 Peptide Drug Industry Development Prospects and Investment Feasibility Evaluation Analysis Report”
Classification of peptide drugs on the global market
Source: PricewaterhouseCoopers
Analysis of the market scale of the peptide drug industry at home and abroad
Global market: In 2020, the global peptide drug market will be about 33 billion U.S. dollars, with a year-on-year growth rate of 8.1%. It is expected that the peptide drug market will grow at a compound annual growth rate of 7.6%, and the market size will exceed 55 billion in 2027. At the dollar level, the peptide drug market still has huge room for growth.
Chinese market: Although my country’s peptide drug market started late, it has developed rapidly. Sales rose from 24.19 billion yuan in 2016 to 29.56 billion yuan in 2020. The average annual growth rate is much higher than the overall growth rate of the global peptide drug market. With the introduction of my country’s policies to encourage the research and development of innovative drugs and promote the consistency evaluation of generic drugs, it is expected that more innovative peptide drugs and peptide generic drugs with significant clinical effects will be approved for marketing in the future, which will further expand the peptide drug market in my country.
Analysis and forecast of domestic competition pattern
In the domestic peptide preparation market, it mainly includes two camps: foreign-funded companies and local companies. The foreign-funded peptide pharmaceutical companies mainly include Novartis, Ferring Pharmaceuticals, Ipsen, Serono, AstraZeneca, Eli Lilly, etc.
Their products are mainly original research drugs, and their product lines cover a wide range and each have their own characteristics. Peptide drugs Sales and other product lines of the company complement each other and form a good synergistic effect. The dosage forms are relatively rich and the competition in the industry is relatively small, such as Novartis’s Octreotide Acetate Microspheres, Eli Lilly’s Exenatide and Teriparatide.
There are nearly one hundred domestic peptide companies. The larger peptide preparation companies include Hanyu Pharmaceutical, Shuangcheng Pharmaceutical, Hainan Zhonghe and other professional peptide pharmaceutical companies, as well as Livzon Group, Xinlitai, and Jiangsu Hao Sen and other large pharmaceutical companies that are newly participating in the peptide drug market.
At present, the products of domestic peptide preparation enterprises are mostly imitating foreign peptide drugs that have passed the patent protection period or have not applied for a patent in my country. The dosage form is relatively single, mainly immunization and emergency hemostatic drugs.
Common freeze-dried powder injection and small-volume injection dosage forms are commonly used. Only a few products have pre-filled injection dosage forms or sustained-release dosage forms. The product similarity is very high, leading to competition in the industry More intense. The number of competing companies in the top four domestic sales categories is more than double digits. Among them, there are as many as 55 competitors for thymopentin.
Intense market competition coupled with the country’s key monitoring of individual large-scale products under the policy of medical insurance control and fee reduction, the sales of traditional products represented by thymopentin and thymus method have shown a flat or obvious downward trend, while Leupronix The market sales of specialty varieties such as Lin, Liraglutide, and Bivarudin, which have few market competitors and recently expired patents, have grown rapidly.
In the future, there will be greater opportunities in the field of new varieties of domestic peptide preparations. At present, nearly half of the peptide drug molecules on the global market have not yet been listed in China. The utilization rate of the top ten peptide molecule products in the global sales is still relatively low in China.
Peptide drugs will have a broad future in the domestic market, such as tumors and diabetes. The market space has great potential for development. Since most local preparation companies lack advanced peptide synthesis technology, do not have the ability to produce peptide APIs or can only produce individual varieties with low technical content, in the future, as the difficulty of peptide drug imitation increases,
a few companies with leading peptide drug research and development capabilities can By imitating the newly expired varieties of patents, controlling the supply of new product raw materials, developing a variety of dosage forms, monopolizing the incremental market of generic drugs after the expiration of the original research drug patents, and realizing corner overtaking with the help of new products, s
uch as our company’s Carbet Oxytocin, Terlipressin from Hanyu Pharmaceutical, Etibatide from Jiangsu Hausen, Bivarudine from Xinlitai, etc. Therefore, the number of approved preparation varieties and dosage forms of peptide drug companies reflects the company’s long-term competitiveness in the industry.
Report directory:
Chapter 1 Overview of the development of China’s peptide drug industry from 2016 to 2021
Section 1 Overview of the development of the peptide drug industry
- Definitions related to the peptide drug industry
- Introduction to the basic situation of the peptide drug industry
- Analysis of the development characteristics of the peptide drug industry
Fourth, the business model of the peptide drug industry
- Production mode
- Purchasing mode
- Sales model
V. Analysis of demand subjects in the peptide drug industry
Section 2 Analysis of the upstream and downstream industrial chain of China’s peptide drug industry
Section 3 Life Cycle Analysis of China’s Peptide Medicine Industry
Section 4 Analysis of Economic Indicators of Peptide Pharmaceutical Industry
- Profitability analysis of peptide drug industry
- Economic cycle analysis of the peptide drug industry
- Analysis of the room for improvement of added value in the peptide drug industry
Section 5 Analysis of Entry Barriers to China’s Peptide Pharmaceutical Industry
- Analysis of financial barriers in the peptide drug industry
- Analysis of technical barriers in the peptide drug industry
- Analysis of talent barriers in the peptide drug industry
Fourth, analysis of brand barriers in the peptide drug industry
V. Analysis of other barriers in the peptide drug industry
Chapter Two 2016-2021 Global Peptide Drug Industry Market Development Status Analysis
Section 1 Review of the development history of the global peptide drug industry
Section 2 Regional distribution of the global peptide drug industry market
Section 3 Regional Market Analysis of Asian Peptide Medicine Industry
- Analysis of the current market situation of the Asian peptide drug industry
- Market prospect analysis of Asian peptide drug industry
Section 4 Regional Market Analysis of North American Peptide Medicine Industry
- Analysis of the market status of the North American peptide drug industry
- Market prospect analysis of North American peptide drug industry
Section 5 Regional Market Analysis of European Peptide Medicine Industry
- Analysis of the current market situation of the European peptide drug industry
- Market prospect analysis of European peptide drug industry
Section 6 Forecast of the distribution trend of the world peptide drug industry from 2021-2027
Section 7 Forecast of the global peptide drug industry market size from 2021-2027
Chapter 3 Analysis of the Development Environment of China’s Peptide Medicine Industry
Section 1 Analysis of my country’s Macroeconomic Environment
Section 2 Analysis of the Policy Environment of China’s Peptide Drug Industry
- The status quo of the industry regulatory system
- Main industry policies and regulations
Section 3 Analysis of the Social Environment Development of China’s Peptide Medicine Industry
Chapter IV Operation of China’s Peptide Drug Industry
Section 1 Introduction to the development status of China’s peptide drug industry
- Review of the development history of the industry
- Industry innovation analysis
- Current status of industry technology development
- Analysis of technology development trends
- Analysis of industry development characteristics
Section 2 Market Scale Analysis of China’s Peptide Drug Industry
Section 3 Analysis of the Supply Situation of China’s Peptide Drug Industry
Section 4 Analysis of Demand in China’s Peptide Medicine Industry
Section 5 Analysis of the Import and Export Situation of my country’s Peptide Pharmaceutical Industry
- Analysis of import situation
- Analysis of export situation
- Comparative analysis of import and export prices
Section VI. Analysis of my country’s Peptide Drug Industry Segmentation Market
- Market segment one
- Market segment two
- Other market segments
Section 7 China’s peptide drug industry supply and demand balance analysis
Section 8 Analysis of the development trend of China’s peptide drug industry
Chapter 5 Operational Data Monitoring of China’s Peptide Drug Industry
Section 1 Analysis of the overall scale of China’s peptide drug industry
- Analysis of enterprise quantity structure
- Industry asset scale analysis
Section 2 Analysis of Production, Sales and Expenses of China’s Peptide Drug Industry
- Current assets
- Sales revenue analysis
- Debt analysis
- Analysis of profit scale
Five, output value analysis
Section 3 Analysis of Financial Indicators of China’s Peptide Drug Industry
- Industry profitability analysis
- Industry solvency analysis
- Analysis of industry operating capability
- Industry development capability analysis
Chapter VI 2016-2021 China’s peptide drug market pattern analysis
Section 1 Analysis of the status quo of competition in China’s peptide drug industry
- Analysis of competition in China’s peptide drug industry
- Analysis of major brands in China’s peptide drug industry
Section 2 Analysis of Concentration Degree of China’s Peptide Medicine Industry
- Analysis of factors affecting market concentration of China’s peptide drug industry
- Market concentration analysis of China’s peptide drug industry
Section 3 Problems Existing in China’s Peptide Pharmaceutical Industry
Section 4 Analysis of China’s Peptide Pharmaceutical Industry’s Problem Solving Strategy
Section 5 Diamond Model Analysis of China’s Peptide Medicine Industry
- Factors of Production
- Requirements
- Support and related industries
- Corporate strategy, structure and competitive status
- The role of the government
Chapter 7 2016-2021 China’s peptide drug industry demand characteristics and dynamic analysis
Section 1 China’s peptide drug industry consumer market dynamics
Section 2 Analysis of the characteristics of the consumer market in China’s peptide drug industry
Section 3 Analysis of the Cost Structure of the Peptide Medicine Industry
Section 4 Analysis of Factors Influencing the Price of Peptide Medicine Industry
Section 5 Analysis of the Price Status Quo of China’s Peptide Drug Industry
Section 6 Forecast of the average price trend of China’s peptide drug industry
- Factors affecting the price of China’s peptide drug industry
- Forecast of the average price trend of China’s peptide drug industry
- China’s peptide drug industry average price growth forecast
Chapter 8 2016-2021 China’s peptide drug industry regional market status analysis
Section 1 Regional market size distribution of China’s peptide drug industry
Section 2 Analysis of the peptide drug market in East China
- Overview of East China
- Analysis of the economic environment in East China
- Analysis of peptide drug market scale in East China
- Forecast of peptide drug market scale in East China
Section 3 Market Analysis in Central China
- Overview of Central China
- Analysis of the economic environment in Central China
- Analysis of peptide drug market scale in Central China
- Forecast of peptide drug market size in Central China
Section 4 Market Analysis in South China
- Overview of South China
- Analysis of the economic environment in South China
- Analysis of peptide drug market scale in South China
- Forecast of peptide drug market size in South China
Chapter 9 2016-2021 China’s peptide drug industry competition
Section 1 Analysis of the competitive structure of China’s peptide drug industry (Porter’s Five Forces Model)
- Competition among existing enterprises
- Analysis of potential entrants
- Threat analysis of substitutes
- Bargaining power of suppliers
- Customer bargaining power
Section 2 Analysis of Concentration Degree of China’s Peptide Medicine Industry
Section 3 Analysis of the Competitive Environment of China’s Peptide Medicine Industry
Chapter 10 Development Analysis of Key Enterprises in the Peptide Pharmaceutical Industry
Section 1 Enterprise A
- Company introduction and product structure overview
- Enterprise operation
- Analysis of the core competitiveness of the enterprise
- Dynamic analysis of enterprise development
Section 2 Enterprise B
- Company introduction and product structure overview
- Enterprise operation
- Analysis of the core competitiveness of the enterprise
- Dynamic analysis of enterprise development
Section 3 Enterprise C
- Company introduction and product structure overview
- Enterprise operation
- Analysis of the core competitiveness of the enterprise
- Dynamic analysis of enterprise development
Section 4 Enterprise D
- Company introduction and product structure overview
- Enterprise operation
- Analysis of the core competitiveness of the enterprise
- Dynamic analysis of enterprise development
Section 5 E Enterprise
- Company introduction and product structure overview
- Enterprise operation
- Analysis of the core competitiveness of the enterprise
- Dynamic analysis of enterprise development
Chapter 11 Analysis and Forecast of the Development Prospects of China’s Peptide Medicine Industry from 2021-2027
Section 1 Analysis of the future development prospects of China’s peptide drug industry
- Analysis of the domestic investment environment of the peptide drug industry
- Analysis of market opportunities in China’s peptide drug industry
- Investment growth forecast of China’s peptide drug industry
Section 2 Forecast of the future development trend of China’s peptide drug industry
Section 3 Market Development Forecast of China’s Peptide Drug Industry
- Market scale forecast of China’s peptide drug industry
- Market scale growth forecast of China’s peptide drug industry
- Forecast of the output value of China’s peptide drug industry
- Forecast of the growth rate of output value of China’s peptide drug industry
V. Forecast of supply and demand of China’s peptide drug industry
Section 4 Forecast of Profit Trend of China’s Peptide Medicine Industry
- Forecast of gross profit of China’s peptide drug industry
- Forecast of total profit of China’s peptide drug industry
Chapter Twelve Investment Risks and Marketing Analysis of China’s Peptide Medicine Industry from 2021-2027
Section 1 Investment Risk Analysis of Peptide Medicine Industry
- Policy risk analysis of the peptide drug industry
- Technical risk analysis of the peptide drug industry
- Competitive risk analysis of the peptide drug industry
- Analysis of other risks in the peptide drug industry
Section 2 Response Strategies of the Peptide Pharmaceutical Industry
- Grasp the opportunity of national investment
- Implementation of Competitive Strategic Alliance
Three, the company’s own response strategy
Chapter 13 Development Strategies and Investment Recommendations of China’s Peptide Medicine Industry from 2021-2027
Section 1 Product Strategy Analysis of China’s Peptide Drug Industry
- Service product development strategy
- Market segmentation strategy
Three, the choice of target market
Section 2 Marketing Channel Strategy of China’s Peptide Drug Industry
- Channel selection strategy for peptide drug industry
- Marketing strategy of peptide drug industry
Section 3 Price Strategy of China’s Peptide Medicine Industry
Section 4 PricewaterhouseCoopers’ Investment Recommendations for the Industry